AMLX(Amylyx Pharmaceuticals, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $285.00K | $22.23M | $380.79M | $87.37M | $0 |
| 毛利润 | — | $19.24M | $355.35M | $81.42M | $0 |
| 营业利润 | −$82.69M | −$201.34M | $38.80M | −$314.73M | −$153.29M |
| 净利润 | −$87.93M | −$198.38M | $49.27M | −$301.74M | −$144.74M |
| 经营现金流 | −$74.80M | −$179.87M | $11.92M | −$167.65M | −$123.34M |
| 自由现金流 | −$75.15M | −$182.40M | $10.68M | −$167.80M | −$123.48M |
| 摊薄每股收益 | $-13.35 | $-3.39 | $0.70 | $-4.43 | $-1.53 |